Quantcast

Latest Clonidine Stories

2014-08-06 08:30:30

RALEIGH, N.C., Aug. 6, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The interim analysis was performed on data from the first 50% of patients who completed the study. The purpose of the interim...

2014-06-26 08:27:08

Top-line results anticipated by end-of-year RALEIGH, N.C., June 26, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the...

2011-05-09 07:00:00

FLORHAM PARK, N.J., May 9, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the publication in Pediatrics of data demonstrating the efficacy of non-stimulant KAPVAY(TM) (clonidine hydrochloride) extended-release tablets when combined with stimulant medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (6-17 years). This study, the first to evaluate KAPVAY in combination with...

2011-01-10 07:20:00

FLORHAM PARK, N.J., Jan. 10, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY(TM), an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. KAPVAY(TM) is the first and only FDA-approved ADHD treatment indicated for use as add-on...

2010-10-04 07:00:00

FLORHAM PARK, N.J., Oct. 4 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of the non-stimulant medication KAPVAY(TM) (clonidine hydrochloride) extended-release tablets, an extended-release oral formulation for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6-17 years. KAPVAY(TM) is the only formulation of clonidine hydrochloride approved...

2010-07-19 06:00:00

PITTSBURGH, July 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS(®), a treatment for hypertension. Clonidine Transdermal System had U.S. sales of...

2009-12-07 05:30:00

SOUTH BRUNSWICK, N.J., Dec. 7 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved its first two New Drug Applications (NDAs) based on its proprietary OralXR+(TM) platform technology including the first-ever 24 hour liquid sustained release product. OralXR+ is a portfolio of dosage forms based on a patent-pending sustained release particles-driven...

2009-11-12 16:43:00

LAKE FOREST, Ill., Nov. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc. (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO) "Bioniche Pharma is very pleased to expand our product line with these injectable drugs," said Steve Thornton, Bioniche...

2009-08-18 17:37:00

WOODCLIFF LAKE, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its licensing partner, Aveva Drug Delivery Systems, has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for a clonidine transdermal system. Clonidine TDS is a generic version of Boehringer Ingelheim's Catapres TTS((R)) and is the first generic seven-day patch indicated in the treatment of hypertension....


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related